# Internal Review - Round 1

## 1. IDENTIFICATION AND EMPIRICAL DESIGN

The paper exploits staggered adoption of civil asset forfeiture reform across 26 U.S. states (2014-2021) using the Callaway-Sant'Anna (2021) doubly-robust estimator. The identification strategy is credible:
- 26 treated states with 24 never-treated controls provides adequate variation
- Event study shows flat pre-trends (Figure 3)
- Not-yet-treated controls avoid bias from already-treated units
- The staggered timing is plausibly exogenous to drug overdose trends

Strengths: The dose-response gradient (abolished > conviction > burden) provides strong evidence for the financial-incentive channel. The monotonicity is consistent with theory and difficult to explain through confounding.

Concerns: The paper does not control for concurrent state-level drug policies (PDMP mandates, naloxone access laws, Good Samaritan laws) that were adopted during overlapping periods. These could confound the forfeiture reform effect if states that reformed forfeiture also adopted other drug-related policies.

## 2. INFERENCE AND STATISTICAL VALIDITY

- Main CS-DiD ATT: -2.71 (SE=1.34, p=0.043) — standard errors clustered at state level
- RI p=0.056 provides finite-sample validation (500 permutations)
- WCB p=0.48 for TWFE (expected given attenuation)
- Leave-one-out range [-3.51, -1.78] demonstrates stability
- Bacon decomposition shows 81.3% clean weight

Sample sizes are now consistent across tables (1,200 for regressions, 900 for summary stats with clear explanation).

## 3. ROBUSTNESS AND ALTERNATIVE EXPLANATIONS

The robustness section is thorough: RI, LOO, Bacon decomposition, WCB, alternative treatment definitions, never-treated controls. The heterogeneity by pre-reform overdose rate serves as a partial placebo.

Missing: No falsification test using an outcome that should NOT be affected by forfeiture reform (e.g., non-drug mortality, traffic fatalities).

## 4. CONTRIBUTION AND LITERATURE POSITIONING

The paper fills a genuine gap — most forfeiture literature is descriptive or legal analysis. The causal design with mortality outcomes is novel. Literature review covers the key references.

## 5. RESULTS INTERPRETATION

The 18% reduction claim (2.71/14.9) is reasonable. The growing treatment effects over time are consistent with gradual reallocation of police effort. The null TWFE result is well-explained as attenuation bias.

## 6. ACTIONABLE REVISION REQUESTS

1. **Must-fix:** Add a falsification test with a non-drug outcome
2. **High-value:** Discuss concurrent drug policy reforms as confounders
3. **Optional:** Consider adding covariates to CS-DiD specification

## 7. OVERALL ASSESSMENT

Strong paper with novel question, credible identification, and interesting results. The dose-response gradient is compelling. Main weakness is lack of falsification test and omitted concurrent policies discussion.

DECISION: MINOR REVISION
